Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GNT002
MIFTS: 55

Giant Cell Glioblastoma

Categories: Neuronal diseases, Rare diseases, Cancer diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Giant Cell Glioblastoma

About this section

MalaCards integrated aliases for Giant Cell Glioblastoma:

Name: Giant Cell Glioblastoma 12 59 55 15 73
Monstrocellular Sarcoma 12 73

Characteristics:

Orphanet epidemiological data:

59
giant cell glioblastoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3074
MeSH 44 D005909
NCIt 50 C4325
SNOMED-CT 68 44529004
Orphanet 59 ORPHA251579
UMLS via Orphanet 74 C0334588
ICD10 via Orphanet 34 C71.9
Sources

Summaries for Giant Cell Glioblastoma

About this section
Disease Ontology : 12 A glioblastoma multiforme that is characterized by a prevalence of bizarre, multinucleated giant cells.

MalaCards based summary : Giant Cell Glioblastoma, also known as monstrocellular sarcoma, is related to glioma susceptibility 1 and papilloma of choroid plexus, and has symptoms including headache and seizures. An important gene associated with Giant Cell Glioblastoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are ERK Signaling and PI3K/AKT activation. The drugs Carmustine and Lomustine have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 The giant-cell glioblastoma is a histological variant of glioblastoma, presenting a prevalence of... more...

Sources

Related Diseases for Giant Cell Glioblastoma

About this section

Diseases related to Giant Cell Glioblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 143)
# Related Disease Score Top Affiliating Genes
1 glioma susceptibility 1 30.2 IDH1 PPARG TP53
2 papilloma of choroid plexus 29.9 GFAP SYP TP53
3 ganglioglioma 29.6 BRAF GFAP SYP TP53
4 gemistocytic astrocytoma 29.5 GFAP PTEN
5 pleomorphic xanthoastrocytoma 29.0 BRAF GFAP IDH1 MGMT SYP TP53
6 glioblastoma 27.0 BRAF EGFR FGFR1 IDH1 MDM2 MGMT
7 glioblastoma multiforme 26.0 EGFR GFAP IDH1 MDM2 MGMT PPARG
8 gliosarcoma 23.6 EGFR FGFR1 FGFR3 GFAP IDH1 LZTR1
9 brain ependymoma 10.8 EGFR TP53
10 nevus of ota 10.8 BRAF TP53
11 papillary tumor of the pineal region 10.7 BRAF SYP
12 plagiocephaly 10.7 FGFR1 FGFR3
13 adult oligodendroglioma 10.7 FGFR1 IDH1
14 oligoastrocytoma 10.6 GFAP MGMT
15 large cell carcinoma 10.6 EGFR FGFR1 SYP
16 desmoplastic infantile ganglioglioma 10.6 GFAP SYP
17 hyperplastic polyposis syndrome 10.6 BRAF TP53
18 pulmonary blastoma 10.6 EGFR SYP TP53
19 basaloid squamous cell carcinoma 10.6 EGFR SYP TP53
20 lung benign neoplasm 10.6 EGFR SYP TP53
21 intracranial chondrosarcoma 10.6 IDH1 TP53
22 non-invasive bladder papillary urothelial neoplasm 10.6 FGFR3 TP53
23 osteoglophonic dysplasia 10.5 FGFR1 FGFR3
24 cerebellar astrocytoma 10.5 IDH1 TP53
25 thymus cancer 10.5 EGFR SYP TP53
26 colorectal adenocarcinoma 10.5 BRAF EGFR TP53
27 lung combined type small cell carcinoma 10.5 GFAP SYP
28 breast carcinoma in situ 10.5 EGFR FGFR1 TP53
29 frontal convexity meningioma 10.5 GFAP TP53
30 gliofibroma 10.4 GFAP TP53
31 anaplastic oligodendroglioma 10.4 EGFR GFAP MGMT
32 rhabdoid meningioma 10.4 BRAF GFAP SYP
33 bladder papillary transitional cell neoplasm 10.4 FGFR3 TP53
34 urinary tract papillary transitional cell benign neoplasm 10.4 FGFR3 TP53
35 adrenocortical carcinoma, hereditary 10.4 BRAF SYP TP53
36 cerebral convexity meningioma 10.3 GFAP TP53
37 protoplasmic astrocytoma 10.3 GFAP TP53
38 chiari malformation 10.3 FGFR3 GFAP SYP
39 atypical follicular adenoma 10.3 SYP TP53
40 cellular ependymoma 10.3 GFAP SYP TP53
41 central nervous system primitive neuroectodermal neoplasm 10.3 GFAP SYP TP53
42 intrahepatic cholangiocarcinoma 10.3 EGFR IDH1 TP53
43 cerebral neuroblastoma 10.3 GFAP SYP TP53
44 cerebral ventricle cancer 10.3 GFAP SYP TP53
45 cerebrum cancer 10.3 GFAP SYP TP53
46 extraventricular neurocytoma 10.3 GFAP IDH1 SYP
47 supratentorial cancer 10.3 GFAP SYP TP53
48 cystic teratoma 10.2 GFAP SYP TP53
49 cerebellar liponeurocytoma 10.2 GFAP SYP TP53
50 dysembryoplastic neuroepithelial tumor 10.2 GFAP IDH1 SYP

Graphical network of the top 20 diseases related to Giant Cell Glioblastoma:



Diseases related to Giant Cell Glioblastoma
Sources

Symptoms & Phenotypes for Giant Cell Glioblastoma

About this section

UMLS symptoms related to Giant Cell Glioblastoma:


headache, seizures

GenomeRNAi Phenotypes related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.98 EGFR
2 Decreased viability GR00173-A 9.98 AURKB
3 Decreased viability GR00221-A-1 9.98 FGFR3 PPARG AURKB EGFR FGFR1
4 Decreased viability GR00221-A-2 9.98 FGFR3 PPARG AURKB FGFR1
5 Decreased viability GR00221-A-3 9.98 FGFR3 PPARG
6 Decreased viability GR00221-A-4 9.98 AURKB PPARG EGFR
7 Decreased viability GR00402-S-2 9.98 FGFR3 PPARG AURKB EGFR FGFR1
8 Decreased substrate adherent cell growth GR00193-A-2 9.55 AURKB
9 Decreased substrate adherent cell growth GR00193-A-3 9.55 BRAF
10 Decreased substrate adherent cell growth GR00193-A-4 9.55 AURKB BRAF FGFR1
11 Decreased cella89culturea89derived Hepatitis C virus (HCVcc; Luca89Jc1) infection GR00234-A-2 9.43 AURKB BRAF EGFR
12 Decreased viability in esophageal squamous lineage GR00235-A 9.32 FGFR3 GFAP IDH1 AURKB PPARG PTEN

MGI Mouse Phenotypes related to Giant Cell Glioblastoma:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.43 MDM2 GFAP NFKBIA PTEN PPARG TACC3
2 growth/size/body region MP:0005378 10.43 MDM2 GFAP IDH1 NFKBIA PTEN PPARG
3 homeostasis/metabolism MP:0005376 10.43 GFAP IDH1 MGMT LZTR1 NFKBIA MDM2
4 mortality/aging MP:0010768 10.4 GFAP IDH1 MGMT LZTR1 NFKBIA MDM2
5 hematopoietic system MP:0005397 10.35 NFKBIA MDM2 IDH1 LZTR1 PTEN PPARG
6 immune system MP:0005387 10.33 NFKBIA MDM2 GFAP IDH1 TACC3 PTEN
7 embryo MP:0005380 10.3 MDM2 PTEN PPARG TACC3 TP53 EGFR
8 endocrine/exocrine gland MP:0005379 10.29 NFKBIA MDM2 MGMT TACC3 PTEN PPARG
9 cardiovascular system MP:0005385 10.28 GFAP MDM2 PTEN PPARG TP53 BRAF
10 integument MP:0010771 10.28 NFKBIA MDM2 PPARG PTEN TP53 AURKB
11 digestive/alimentary MP:0005381 10.21 MDM2 GFAP PTEN TP53 BRAF FGFR1
12 neoplasm MP:0002006 10.2 MGMT MDM2 PPARG TACC3 PTEN TP53
13 normal MP:0002873 10.18 NFKBIA MDM2 PPARG SYP TACC3 PTEN
14 craniofacial MP:0005382 10.16 MDM2 TACC3 TP53 BRAF FGFR3 FGFR1
15 muscle MP:0005369 10.13 MDM2 GFAP PTEN PPARG TP53 EGFR
16 adipose tissue MP:0005375 10.1 PTEN PPARG TP53 BRAF BUB3 EGFR
17 limbs/digits/tail MP:0005371 10.07 MDM2 TACC3 PTEN TP53 FGFR1 EGFR
18 hearing/vestibular/ear MP:0005377 10.05 PPARG TP53 BRAF FGFR3 FGFR1 EGFR
19 liver/biliary system MP:0005370 10.05 MDM2 PTEN PPARG TACC3 TP53 BRAF
20 no phenotypic analysis MP:0003012 10.03 MDM2 MGMT PPARG TP53 AURKB FGFR1
21 renal/urinary system MP:0005367 9.92 MDM2 PTEN PPARG TP53 BRAF FGFR1
22 reproductive system MP:0005389 9.91 MDM2 PTEN PPARG TP53 BRAF AURKB
23 pigmentation MP:0001186 9.77 MDM2 PTEN TP53 BRAF EGFR
24 respiratory system MP:0005388 9.7 IDH1 MGMT PTEN TP53 BRAF FGFR3
25 skeleton MP:0005390 9.7 MDM2 IDH1 PTEN PPARG TACC3 TP53
26 vision/eye MP:0005391 9.28 GFAP PTEN PPARG TP53 BUB3 BRAF
Sources

Drugs & Therapeutics for Giant Cell Glioblastoma

About this section

Drugs for Giant Cell Glioblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 357)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1 154-93-8 2578
2
Lomustine Approved, Investigational Phase 3,Phase 1 13010-47-4 3950
3
Procarbazine Approved, Investigational Phase 3,Phase 1,Phase 2 671-16-9 4915
4
Trioxsalen Approved Phase 3,Phase 1 3902-71-4 5585
5
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
6
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
7
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
8
Vincristine Approved, Investigational Phase 3,Phase 1 2068-78-2, 57-22-7 5978
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
10
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
11
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
12
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
13
Dopamine Approved Phase 3,Not Applicable 51-61-6, 62-31-7 681
14
Cyproheptadine Approved Phase 3 129-03-3 2913
15
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
16
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538 444795
17 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
18 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Dermatologic Agents Phase 3,Phase 1,Phase 2,Not Applicable
21 Dihematoporphyrin Ether Phase 3,Phase 1
22 Ether Phase 3
23 Photosensitizing Agents Phase 3,Phase 1,Phase 2
24 Antirheumatic Agents Phase 3,Phase 1,Phase 2,Not Applicable
25 Immunosuppressive Agents Phase 3,Phase 1,Phase 2,Not Applicable
26 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
27 O(6)-benzylguanine Phase 3,Phase 2,Phase 1,Not Applicable
28 Anesthetics Phase 3
29 Anesthetics, General Phase 3
30 Anesthetics, Inhalation Phase 3
31 Hematoporphyrin Derivative Phase 3
32 Hematoporphyrins Phase 3
33 Antimitotic Agents Phase 3,Phase 1,Phase 2
34 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Early Phase 1
35 Adjuvants, Anesthesia Phase 3
36 Analgesics Phase 3,Phase 2,Phase 1
37 Analgesics, Opioid Phase 3
38 Anesthetics, Intravenous Phase 3
39 Liver Extracts Phase 3,Phase 2,Phase 1
40 Narcotics Phase 3
41 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
42 Cholinergic Agents Phase 3,Phase 2
43 Cholinesterase Inhibitors Phase 3,Phase 2
44 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
45 Nootropic Agents Phase 3,Phase 2
46 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable
47 Central Nervous System Stimulants Phase 3,Phase 2
48 Dopamine Agents Phase 3,Not Applicable
49 Anti-Allergic Agents Phase 3
50 Antipruritics Phase 3

Interventional clinical trials:

(show top 50) (show all 339)
# Name Status NCT ID Phase Drugs
1 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
2 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
3 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3 temozolomide
4 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
5 Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme Completed NCT00002545 Phase 3 carmustine
6 Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00006353 Phase 3 temozolomide
7 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
8 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
9 SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
10 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
11 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
12 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
13 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
15 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
17 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
18 Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Unknown status NCT01013285 Phase 2 temozolomide
19 Radiation Therapy Plus Hyperbaric Oxygen in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Unknown status NCT00006460 Phase 1, Phase 2 hyperbaric oxygen
20 Hydroxychloroquine, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Unknown status NCT00486603 Phase 1, Phase 2 hydroxychloroquine;temozolomide
21 Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas Unknown status NCT00492687 Phase 2 carboplatin;tamoxifen citrate;temozolomide
22 Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme Unknown status NCT00014105 Phase 1, Phase 2 carboplatin;temozolomide
23 Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme Unknown status NCT00054496 Phase 2 erlotinib hydrochloride
24 Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Unknown status NCT00006656 Phase 2 carmustine in ethanol
25 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
26 Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Completed NCT00662506 Phase 1, Phase 2 Cediranib Maleate;Temozolomide
27 Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Completed NCT00305864 Phase 1, Phase 2 Motexafin Gadolinium;Temozolomide
28 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00085254 Phase 1, Phase 2 cilengitide;temozolomide
29 Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM Completed NCT00004146 Phase 2 carboxyamidotriazole
30 Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00014170 Phase 2 gefitinib
31 Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00058097 Phase 2 tipifarnib
32 Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme Completed NCT00052208 Phase 1, Phase 2 gefitinib
33 Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors Completed NCT00039494 Phase 2 erlotinib hydrochloride;temozolomide
34 Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma Completed NCT01753713 Phase 2 dovitinib
35 GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery Completed NCT00980343 Phase 2 vismodegib
36 Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme Completed NCT00641706 Phase 2 vorinostat;bortezomib
37 Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Completed NCT00540722 Phase 2 R-(-)-gossypol acetic acid
38 Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma Completed NCT01310868 Phase 2 5-ALA;Gliadel wafers;Concomitant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist;Adjuvant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist
39 Pazopanib in Treating Patients With Recurrent Glioblastoma Completed NCT00459381 Phase 2 pazopanib hydrochloride
40 Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Completed NCT00445588 Phase 2 erlotinib hydrochloride;sorafenib tosylate
41 Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Completed NCT00335764 Phase 1, Phase 2 sorafenib tosylate;erlotinib hydrochloride;tipifarnib;temsirolimus
42 AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme Completed NCT00305656 Phase 2 cediranib maleate
43 Boron Neutron Capture Therapy, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00974987 Phase 2 TMZ(temozolomide)
44 Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Completed NCT00238303 Phase 2 vorinostat
45 Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00643097 Phase 2 Temozolomide
46 CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme Completed NCT00016328 Phase 2 temsirolimus
47 Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme Completed NCT00112502 Phase 2 Celecoxib;Isotretinoin;Temozolomide;Thalidomide
48 Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00099125 Phase 2 irinotecan hydrochloride;temozolomide
49 Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme Completed NCT00099060 Phase 1, Phase 2 lapatinib ditosylate
50 A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas Completed NCT00045708 Phase 1, Phase 2 ixabepilone;Anticonvulsant

Search NIH Clinical Center for Giant Cell Glioblastoma

Sources

Genetic Tests for Giant Cell Glioblastoma

About this section
Sources

Anatomical Context for Giant Cell Glioblastoma

About this section

MalaCards organs/tissues related to Giant Cell Glioblastoma:

41
Brain, Bone, Bone Marrow, T Cells, Liver, Prostate, Endothelial
Sources

Publications for Giant Cell Glioblastoma

About this section

Articles related to Giant Cell Glioblastoma:

(show top 50) (show all 54)
# Title Authors Year
1
Giant Cell Glioblastoma in a Child with Clinical and Family History of Neurofibromatosis. ( 29114311 )
2017
2
IDH-mutant giant cell glioblastoma: A neglected tumor variant? ( 29035191 )
2017
3
MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma. ( 27253461 )
2016
4
Pediatric Giant Cell Glioblastoma Mimicking Hemorrhage Secondary to Ischemic Stroke. ( 26344331 )
2015
5
Giant cell glioblastoma with calcification and long-term survival. ( 26960525 )
2015
6
Genetic alterations in gliosarcoma and giant cell glioblastoma. ( 26443480 )
2015
7
Survival outcomes of giant cell glioblastoma: Institutional experience in the management of 20 patients. ( 25037316 )
2014
8
Cerebellar giant cell glioblastoma multiforme in an adult. ( 25002780 )
2014
9
Giant cell glioblastoma in the pediatric age group: Report of two cases. ( 23772243 )
2013
10
Giant-cell glioblastoma of childhood associated with HIV-1 and JC virus coinfection. ( 23702739 )
2013
11
Recurrent giant cell glioblastoma with the neuroradiologic picture of multiple meningiomas. ( 22241593 )
2013
12
Giant cell glioblastoma with unique bilateral cerebellopontine angle localization considered as extraaxial tumor growth in a patient with neurofibromatosis Type 1. ( 22943956 )
2013
13
Magnetic resonance imaging and computed tomography findings in pediatric giant cell glioblastoma. ( 22286149 )
2012
14
Giant cell glioblastoma in a child: A rare case report. ( 23293671 )
2012
15
Cytomorphology of giant cell glioblastoma: Report of a case and brief review of literature. ( 21319330 )
2012
16
Acute tetraplegia and cardiac arrest following high cervical leptomeningeal metastasis of giant cell glioblastoma. ( 21658953 )
2011
17
Giant cell glioblastoma in the cerebrum of a Pembroke Welsh corgi. ( 21146179 )
2011
18
CD34 expression in glioblastoma and giant cell glioblastoma. ( 20175958 )
2010
19
A case of giant cell glioblastoma: a mimicker of a cerebral metastasis. ( 20973333 )
2010
20
Giant cell glioblastoma is associated with altered aurora b expression and concomitant p53 mutation. ( 20467329 )
2010
21
Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis. ( 19332771 )
2009
22
Exophytic giant cell glioblastoma of the medulla oblongata. ( 19061354 )
2009
23
Pediatric giant cell glioblastoma: New insights into a rare tumor entity. ( 19050301 )
2009
24
Long-Term Survival of a Patient with Giant Cell Glioblastoma: Case Report and Review of the Literature. ( 20740171 )
2009
25
Giant cell glioblastoma: review of the literature and illustrated case. ( 18726045 )
2008
26
Cytogenetic and molecular genetic analyses of giant cell glioblastoma multiforme reveal distinct profiles in giant cell and non-giant cell subpopulations. ( 17498554 )
2007
27
Cytologic characteristics of subependymal giant cell astrocytoma in squash smears: morphometric comparisons with gemistocytic astrocytoma and giant cell glioblastoma. ( 17536538 )
2007
28
Giant cell glioblastoma multiforme: report of a case with prolonged survival and transformation to gliosarcoma. ( 16133270 )
2006
29
Pediatric giant cell glioblastoma: a case report and review of the literature. ( 15999285 )
2006
30
Lipidized giant-cell glioblastoma of cerebellum. ( 16320820 )
2005
31
Giant cell glioblastoma and pleomorphic xanthoastrocytoma. ( 15043454 )
2004
32
Heavily lipidized, calcified giant cell glioblastoma in an 8-year-old patient, associated with neurofibromatosis type 1 (NF1): report of a case with long-term survival. ( 15584213 )
2004
33
Giant cell glioblastoma and pleomorphic xanthoastrocytoma show different immunohistochemical profiles for neuronal antigens and p53 but share reactivity for class III beta-tubulin. ( 12946225 )
2003
34
Giant cell glioblastoma manifesting as traumatic intracerebral hemorrhage--case report. ( 12513031 )
2002
35
Long-term survival of a patient with giant cell glioblastoma. Case report. ( 11302659 )
2001
36
Spinal leptomeningeal metastases of giant cell glioblastoma associated with subarachnoid haemorrhage: case report. ( 11148082 )
2001
37
Genetic profile of the giant cell glioblastoma. ( 10068201 )
1999
38
Malignant supratentorial ganglioglioma (ganglion cell-giant cell glioblastoma): a case report and review of the literature. ( 10320149 )
1999
39
Favorable outcome of giant cell glioblastoma in a child. Report of an 11-year survival period. ( 9694343 )
1998
40
p53 mutations versus EGF receptor expression in giant cell glioblastomas. ( 9370234 )
1997
41
Molecular genetic analysis of giant cell glioblastomas. ( 9284834 )
1997
42
A clinico-immunohistochemical study of giant cell glioblastoma. ( 8916121 )
1996
43
Immunohistochemical analysis of giant cell glioblastoma. ( 7550996 )
1995
44
Giant cell glioblastoma in the frontal cortex of a dog. ( 7771064 )
1995
45
Multifocal giant cell glioblastoma: case report. ( 8362353 )
1993
46
Giant cell glioblastoma in a Syrian hamster. ( 1771744 )
1991
47
Kinetics and glial fibrillary acidic (GFA) protein production in a transplantable human giant cell glioblastoma (D-212 MG) of near haploid karyotype maintained in an organ culture system. An immunohistochemistry study. ( 2320202 )
1990
48
Giant cell glioblastoma: a work-up of 2 cases with long survival. ( 2718738 )
1989
49
A serially transplantable human giant cell glioblastoma that maintains a near-haploid stem line. ( 3840409 )
1985
50
Choroid plexus papilloma and giant cell glioblastoma induced in hamsters with bovine adenovirus type 3. ( 4013674 )
1985
Sources

Variations for Giant Cell Glioblastoma

About this section
Sources

Expression for Giant Cell Glioblastoma

About this section
Search GEO for disease gene expression data for Giant Cell Glioblastoma.
Sources

Pathways for Giant Cell Glioblastoma

About this section

Pathways related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

(show all 43)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 64
Show member pathways
 13.84 AURKB BRAF EGFR FGFR1 FGFR3 GFAP
2
PI3K/AKT activation 66
Show member pathways
 13.09 EGFR FGFR1 FGFR3 MDM2 PTEN TP53
3
Phospholipase-C Pathway 64
Show member pathways
 13.01 BRAF EGFR FGFR1 FGFR3 MDM2 PTEN
4
PI3K-Akt signaling pathway 37
Show member pathways
 12.96 EGFR FGFR1 FGFR3 MDM2 PTEN TP53
5
NFAT and Cardiac Hypertrophy 64
Show member pathways
 12.84 BRAF EGFR FGFR1 FGFR3 NFKBIA PTEN
6
MAPK signaling pathway 1 37
12.74 BRAF EGFR FGFR1 FGFR3 TP53
7
Gastric cancer 37
Show member pathways
 12.74 BRAF EGFR FGFR1 PTEN TP53
8
Endometrial cancer 37
Show member pathways
 12.72 BRAF EGFR FGFR1 MDM2 NFKBIA PPARG
9
Glioma 37
Show member pathways
 12.69 BRAF EGFR FGFR1 FGFR3 MDM2 PTEN
10
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.62 EGFR FGFR1 FGFR3 MDM2 NFKBIA PTEN
11
Pathways in cancer 37
12.53 BRAF EGFR FGFR1 FGFR3 MDM2 NFKBIA
12
Development EGFR signaling pathway 22
Show member pathways
 12.52 BRAF EGFR MDM2 NFKBIA TP53
13
MicroRNAs in cancer 37
12.48 EGFR FGFR3 MDM2 PTEN TP53
14
DNA Damage 4
12.47 AURKB BUB3 MDM2 MGMT TACC3 TP53
15
mTOR signaling pathway (KEGG) 65
Show member pathways
 12.45 BRAF EGFR FGFR1 FGFR3 PTEN TP53
16
ErbB signaling pathway 1 37
Show member pathways
 12.44 BRAF EGFR MDM2 TP53
17
Apoptosis Pathway 72
Show member pathways
 12.39 EGFR FGFR1 FGFR3 MDM2 NFKBIA TP53
18
Proteoglycans in cancer 37
12.26 BRAF EGFR FGFR1 MDM2 TP53
19
VEGF Signaling Pathway 67 61
Show member pathways
 12.21 EGFR FGFR1 FGFR3 PTEN
20
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 12.19 BRAF NFKBIA PPARG TP53
21
Integrated Breast Cancer Pathway 1
12.12 BRAF EGFR MDM2 PTEN TP53
22
FoxO signaling pathway 37
Show member pathways
 12.07 BRAF EGFR MDM2 PTEN
23
Direct p53 effectors 1
12.04 EGFR MDM2 PTEN TP53
24
AKT Signaling Pathway 67
12.04 EGFR FGFR1 FGFR3 MDM2 PTEN TP53
25
Hepatitis C 37
12.03 BRAF EGFR NFKBIA TP53
26
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 12.03 BRAF EGFR FGFR1 FGFR3
27
Development IGF-1 receptor signaling 22
Show member pathways
 12 MDM2 NFKBIA PTEN TP53
28
MAPK Pathway 72
Show member pathways
 11.99 BRAF EGFR NFKBIA TP53
29
Senescence and Autophagy in Cancer 1
11.91 BRAF MDM2 PTEN TP53
30
Small cell lung cancer 37
11.83 NFKBIA PTEN TP53
31
Androgen receptor signaling pathway 1
11.82 EGFR MDM2 PTEN
32
ATM Pathway 64
Show member pathways
 11.8 MDM2 NFKBIA TP53
33
Glioblastoma Multiforme 64
11.78 BRAF EGFR MDM2 MGMT PTEN TP53
34
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.77 FGFR1 FGFR3 GFAP SYP
35
Bladder cancer 37 1
11.58 BRAF EGFR FGFR3 MDM2 TP53
36
Copper homeostasis 1
11.57 MDM2 PTEN TP53
37
Proteolysis Putative SUMO-1 pathway 22
Show member pathways
 11.57 MDM2 NFKBIA TP53
38
Integrated Cancer Pathway 1
11.49 MDM2 PTEN TP53
39
Alzheimers Disease Pathway 64
11.48 EGFR FGFR1 FGFR3
40
DNA damage_ATM/ATR regulation of G1/S checkpoint 22
11.46 MDM2 NFKBIA TP53
41
Vemurafenib Pathway, Pharmacodynamics 61
11.38 BRAF EGFR FGFR1 FGFR3
42
Central carbon metabolism in cancer 37
11.25 EGFR FGFR1 FGFR3 IDH1 PTEN TP53
43
Aurora A signaling 1
10.59 AURKB MDM2 NFKBIA TACC1 TACC3 TP53
Sources

GO Terms for Giant Cell Glioblastoma

About this section

Cellular components related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.73 AURKB BRAF BUB3 FGFR1 GFAP IDH1
2 cytoplasm GO:0005737 9.5 AURKB BRAF EGFR FGFR1 FGFR3 GFAP

Biological processes related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 protein deubiquitination GO:0016579 9.92 MDM2 NFKBIA PTEN TP53
2 MAPK cascade GO:0000165 9.91 BRAF EGFR FGFR1 FGFR3
3 cell cycle GO:0007049 9.91 AURKB BUB3 SEPT14 TACC1 TACC3 TP53
4 regulation of cell proliferation GO:0042127 9.88 BRAF EGFR FGFR1 NFKBIA
5 cell division GO:0051301 9.88 AURKB BUB3 SEPT14 TACC1 TACC3
6 protein autophosphorylation GO:0046777 9.76 AURKB EGFR FGFR1 FGFR3
7 cellular response to organic cyclic compound GO:0071407 9.73 MDM2 MGMT NFKBIA
8 positive regulation of kinase activity GO:0033674 9.71 EGFR FGFR1 FGFR3
9 cellular response to drug GO:0035690 9.7 BRAF EGFR TP53
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.65 BRAF EGFR FGFR1 FGFR3 PTEN
11 cell proliferation GO:0008283 9.63 AURKB EGFR PTEN TACC1 TACC3 TP53
12 negative regulation of signal transduction GO:0009968 9.62 BRAF EGFR FGFR1 FGFR3
13 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.61 NFKBIA PPARG
14 regulation of chromosome segregation GO:0051983 9.59 AURKB BUB3
15 negative regulation of telomerase activity GO:0051974 9.58 PPARG TP53
16 long-term synaptic potentiation GO:0060291 9.58 BRAF GFAP PTEN
17 salivary gland morphogenesis GO:0007435 9.57 EGFR FGFR1
18 attachment of spindle microtubules to kinetochore GO:0008608 9.55 AURKB BUB3
19 positive regulation of phospholipase activity GO:0010518 9.51 FGFR1 FGFR3
20 regulation of axon regeneration GO:0048679 9.49 BRAF PTEN
21 cellular response to actinomycin D GO:0072717 9.37 MDM2 TP53
22 response to organic cyclic compound GO:0014070 9.35 EGFR IDH1 MGMT PPARG PTEN
23 negative regulation of apoptotic process GO:0043066 9.28 BRAF EGFR FGFR1 FGFR3 MDM2 MGMT
24 positive regulation of cell proliferation GO:0008284 10 EGFR FGFR1 FGFR3 MDM2 PTEN

Molecular functions related to Giant Cell Glioblastoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.89 AURKB BRAF EGFR FGFR1 FGFR3
2 nucleotide binding GO:0000166 9.77 AURKB BRAF EGFR FGFR1 FGFR3
3 protein phosphatase binding GO:0019903 9.65 EGFR PPARG TP53
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.63 EGFR FGFR1 FGFR3
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.61 EGFR FGFR1 FGFR3
6 protein self-association GO:0043621 9.58 PPARG SYP TP53
7 MAP kinase kinase kinase activity GO:0004709 9.56 BRAF EGFR FGFR1 FGFR3
8 mitogen-activated protein kinase kinase binding GO:0031434 9.46 BRAF EGFR FGFR1 FGFR3
9 enzyme binding GO:0019899 9.43 EGFR MDM2 NFKBIA PPARG PTEN TP53
10 identical protein binding GO:0042802 9.4 BRAF EGFR FGFR1 FGFR3 GFAP IDH1
11 fibroblast growth factor-activated receptor activity GO:0005007 9.32 FGFR1 FGFR3
Sources

Sources for Giant Cell Glioblastoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....